Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk
- PMID: 34631754
- PMCID: PMC8495009
- DOI: 10.3389/fmed.2021.737079
Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory disease primarily affecting peripheral and axial joints, with the possible presence of extra-articular manifestations (EAMs), such as psoriasis, uveitis, and inflammatory bowel disease. Recently, the concept of psoriatic disease (PsD) has been proposed to define a systemic condition encompassing, in addition to joints and EAMs, some comorbidities (e.g., metabolic syndrome, type II diabetes, hypertension) that can affect the disease outcome and the achievement of remission. EAMs and comorbidities in PsA share common immunopathogenic pathways linked to the systemic inflammation of this disease; these involve a broad variety of immune cells and cytokines. Currently, various therapeutics are available targeting different cytokines and molecules implicated in the inflammatory response of this condition; however, despite an improvement in the management of PsA, comprehensive disease control is often not achievable. There is, therefore, a big gap to fill especially in terms of comorbidities and EAMs management. In this review, we summarize the clinical aspects of the main comorbidities and EAMs in PsA, and we focus on the immunopathologic features they share with the articular manifestations. Moreover, we discuss the effect of a diverse immunomodulation and the current unmet needs in PsD.
Keywords: comorbidities; extra-articular manifestations; immunomodulation; psoriatic arthritis; psoriatic disease; systemic inflammation.
Copyright © 2021 Novelli, Lubrano, Venerito, Perrotta, Marando, Curradi and Iannone.
Conflict of interest statement
FM, LN, and GC, are AbbVie employees and may own AbbVie stocks/options. FI has received consultancy fees and/or speaker honoraria from Actelion, Pfizer, AbbVie, Janssen, Celgene, Novartis, MSD, BMS, UCB, Sobi, Roche, Sanofi outside this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis.Front Med (Lausanne). 2021 Sep 16;8:737256. doi: 10.3389/fmed.2021.737256. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34604268 Free PMC article. Review.
-
Extra-articular manifestations in psoriatic arthritis patients.Clin Rheumatol. 2015 Apr;34(4):745-53. doi: 10.1007/s10067-014-2652-9. Epub 2014 May 8. Clin Rheumatol. 2015. PMID: 24803233
-
The cardiometabolic conditions of psoriatic disease.Front Immunol. 2022 Sep 8;13:970371. doi: 10.3389/fimmu.2022.970371. eCollection 2022. Front Immunol. 2022. PMID: 36159785 Free PMC article. Review.
-
Psoriatic arthritis: complexities, comorbidities and implications for the clinic.Expert Rev Clin Immunol. 2016;12(4):405-16. doi: 10.1586/1744666X.2016.1139453. Epub 2016 Jan 28. Expert Rev Clin Immunol. 2016. PMID: 26735626 Review.
-
JAK Inhibitors in Psoriatic Disease.Clin Cosmet Investig Dermatol. 2023 Oct 31;16:3129-3145. doi: 10.2147/CCID.S433367. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37927384 Free PMC article. Review.
Cited by
-
Genetic Variants of the NF-κB Pathway: Unraveling the Genetic Architecture of Psoriatic Disease.Int J Mol Sci. 2021 Nov 30;22(23):13004. doi: 10.3390/ijms222313004. Int J Mol Sci. 2021. PMID: 34884808 Free PMC article. Review.
-
Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice.Diagnostics (Basel). 2024 Jul 30;14(15):1637. doi: 10.3390/diagnostics14151637. Diagnostics (Basel). 2024. PMID: 39125513 Free PMC article. Review.
-
A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab.Front Immunol. 2022 Jun 27;13:917939. doi: 10.3389/fimmu.2022.917939. eCollection 2022. Front Immunol. 2022. PMID: 35833126 Free PMC article.
-
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis Patients.J Clin Med. 2025 Jun 10;14(12):4111. doi: 10.3390/jcm14124111. J Clin Med. 2025. PMID: 40565857 Free PMC article.
-
Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study.RMD Open. 2023 Jan;9(1):e002533. doi: 10.1136/rmdopen-2022-002533. RMD Open. 2023. PMID: 36650006 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous